Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. The company is focusing its efforts and resources on the continued research and development of barzolvolimab and CDX-622.

The company faces intense competition from many companies in the United States and abroad, including a number of large pharmaceutical companies. Competitors named in the filing that have initiated a Phase 3 study or have obtained marketing approval for a potentially competitive drug to barzolvolimab include Abbvie, Akeso Bio, Amgen/Kiowa Kirin, Celltrion, Eli Lilly, Galderma/Chugai, Genentech/Novartis, Incyte, Kashiv Biosciences, Leo Pharma, Medimetriks, Novartis, Pfizer, Regeneron/Sanofi, Sanofi, Teva, and Vanda Pharmaceuticals. The company believes its program assets provide strategic options to either retain full economic rights to its innovative therapies or seek favorable economic terms through advantageous commercial partnerships.

The company generates revenue from product development agreements with collaborative partners for the research and development of therapeutic drug candidates, and from manufacturing and research and development arrangements. Revenue from product development agreements is generally recognized using a cost-to-cost measure of progress, while revenue from time-and-material contracts is recognized on an output basis as labor hours and/or direct expenses are incurred. The company has had no commercial revenues from sales of its drug candidates.

The company's primary drug candidate is barzolvolimab, a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT and potently inhibits its activity. Barzolvolimab is currently being studied across multiple mast cell driven diseases including Chronic Spontaneous Urticaria (CSU), Cold Urticaria (ColdU) and Symptomatic Dermographism (SD), Prurigo Nodularis (PN), and Atopic Dermatitis (AD). In CSU, the company initiated two Phase 3 studies in July 2024, and in February 2026 announced enrollment is complete with topline data expected in the fourth quarter of 2026. In ColdU and SD, a Phase 3 study was initiated in December 2025 and enrollment is ongoing. In PN, a Phase 2 study was initiated in April 2024 and enrollment was completed in December 2025, with topline data expected in summer 2026. In AD, a Phase 2 study was initiated in December 2024 and enrollment was completed in January 2026, with topline data expected in late 2026.

The company's next generation bispecific antibody platform supports pipeline expansion with additional candidates for inflammatory diseases. CDX-622 is the first bispecific candidate, targeting two complementary pathways that drive chronic inflammation by neutralizing thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. In November 2024, a Phase 1a dose-escalation study in healthy volunteers was initiated and enrollment was completed in January 2026. Data from the multiple ascending dose portion of the study and subcutaneous administration are anticipated in the third quarter of 2026. In January 2026, an open-label, single-dose Phase 1 proof of mechanism study was initiated in adults with mild to moderate asthma.

In August 2025, the company announced the discontinuation of development in eosinophilic esophagitis (EoE) based on interim results from a Phase 2 study. In November 2023, the company issued 8,538,750 ¹ shares of common stock in an underwritten public offering resulting in net proceeds of $216.2 million ². In March 2024, the company issued 9,798,000 ³ shares of common stock in an underwritten public offering resulting in net proceeds of $432.3 million ⁴. On February 26, 2024, the company entered into a controlled equity offering sales agreement with Cantor Fitzgerald & Co. to allow the issuance and sale of shares of common stock from time to time, with $300.0 million ⁵ registered for sale, all of which remained unsold as of December 31, 2025. On November 10, 2025, the company announced the appointment of a new Chief Commercial Officer.

Total revenues for the year ended December 31, 2025 were $1.545 million ⁶, compared to $7.020 million ⁷ for the year ended December 31, 2024. Net loss for the year ended December 31, 2025 was $258.757 million ⁸, compared to $157.863 million ⁹ for the year ended December 31, 2024. Research and development expenses were $245.074 million ¹⁰ for 2025, compared to $163.550 million ¹¹ for 2024. The company had an accumulated deficit of $1.8 billion ¹² as of December 31, 2025.

A major growth vector is the continued development of barzolvolimab across multiple mast cell driven diseases. In CSU, the company initiated two Phase 3 studies (EMBARQ-CSU1 and EMBARQ-CSU2) in July 2024, which are global studies with approximately 40 countries and 250 sites per study, where approximately 915 ¹³ patients per trial will be randomized. Enrollment was completed in February 2026 with 1,939 ¹⁴ patients enrolled, and topline data is expected in Q4 2026. In ColdU and SD, a Phase 3 study (EMBARQ-ColdU and SD) was initiated in December 2025, a global study with approximately 75 clinical trial sites across 7 countries where approximately 240 ¹⁵ participants will be enrolled. In PN, a Phase 2 study was initiated in April 2024 with approximately 120 ¹⁶ patients, and enrollment was completed in December 2025 with topline data expected in summer 2026. In AD, a Phase 2 study was initiated in December 2024 with approximately 120 ¹⁷ patients, and enrollment was completed in January 2026 with topline data expected in late 2026.

Another growth vector is the bispecific antibody platform and CDX-622. The Phase 1a dose-escalation study in healthy volunteers was initiated in November 2024 and enrollment was completed in January 2026. Data from the multiple ascending dose portion of the study and subcutaneous administration are anticipated in the third quarter of 2026. In January 2026, an open-label, single-dose Phase 1 proof of mechanism study was initiated in adults with mild to moderate asthma. The company continues to assess potential opportunities for barzolvolimab in other diseases where mast cells play an important role, such as dermatologic, respiratory, allergic, gastrointestinal and ophthalmic conditions.The barzolvolimab manufacturing process has been successfully transferred and scaled up to produce larger cGMP batches at both Drug Substance (DS) and Drug Product (DP) commercial Contract Development and Manufacturing Organizations in support of late-stage trials and to prepare for potential commercialization. Drug product manufacturing into 1 mL pre-filled syringes has been completed and pre-filled syringes are actively being used in Phase 3 trials. In 2025, the company initiated the Process Performance Qualification (PPQ) manufacturing runs for DS and anticipates the completion of those activities in 2026. The company is currently preparing for the DP PPQ activities and expects to complete these activities in 2026. The company currently operates its own cGMP manufacturing facility in Fall River, Massachusetts, to produce drug substance for current and planned early-stage clinical trials.

The company expects to spend substantial funds to continue the research, development and testing of its products. Research and development expenses were $245.1 million ¹⁸ for the year ended December 31, 2025. The company expects that a significant portion of its operating expenses will continue to be related to research and development in 2026. As of December 31, 2025, the company had cash, cash equivalents and marketable securities of $518.6 million ¹⁹. The company believes this is sufficient to meet estimated working capital requirements and fund current planned operations through 2027. The company may take further steps to raise additional capital to meet long-term liquidity needs, including licensing of drug candidates, possible business combinations, issuance of debt, or issuance of common stock or other securities.

The company faces significant competition from many companies with substantially greater financial, technical and human resources. Competitors may succeed in obtaining regulatory approval for drugs more rapidly. The company also faces risks related to the need for additional capital to fund operations, as it has had no product revenue and an accumulated deficit of $1.8 billion ²⁰ as of December 31, 2025. The company expects to incur an operating loss in 2026 and beyond. The company is subject to extensive regulatory scrutiny and the drug approval process is lengthy and uncertain.

The company faces risks related to the extensive and lengthy regulatory scrutiny to which it is subject, including the need to obtain regulatory approval from the FDA and comparable authorities in other countries. Disruptions at the U.S. FDA and other government agencies caused by funding shortages or otherwise could hinder their ability to review and process regulatory submissions. The company also faces risks related to its ability to commence, enroll, manage and complete clinical trials, including difficulty in enrolling patients. The company may have delays in commencing, enrolling and completing clinical trials, and may not complete them at all.

The company currently has no product revenue and an accumulated deficit of $1.8 billion ²¹ as of December 31, 2025, and will need to raise additional capital to fund operations. If the company is unable to raise funds, it may have to delay or discontinue development of one or more programs. The company faces intense competition from companies with substantially greater resources, and competitors may obtain regulatory approval for products more rapidly. The company's drug candidates are subject to extensive and lengthy regulatory scrutiny, and the FDA may not approve them. The company relies on third parties, including single source contract development and manufacturing organizations, and any failures could cause delays in clinical studies or commercialization. The company may be required to pay a milestone payment of $52,500,000 ²² to former Kolltan stockholders upon achievement of certain regulatory approvals, which could be paid in cash or stock, potentially causing dilution.

Management's message emphasizes the company's focus on exploring the science of mast cell biology and developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Key strategic priorities include advancing barzolvolimab through late-stage clinical trials across multiple indications, expanding the pipeline through the bispecific antibody platform with CDX-622, and building a fully integrated, commercial-stage biopharmaceutical company. Management believes the program assets provide strategic options to either retain full economic rights or seek favorable economic terms through partnerships.